Adenosine receptors as therapeutic targets for chronic rhinosinusitis
Adenosine receptors as therapeutic targets for chronic rhinosinusitis
批准号:
8243944
负责人:
Xiaoyang Hua
金额:
$18.5万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-02-01 至 2014-01-31
关键词:
AdenosineAffectAgeAgonistAmericanAnti-Inflammatory AgentsAnti-inflammatoryAsthmaAttenuatedBiologicalBiologyBloodBreathingCessation of lifeChronicChronic Obstructive Airway DiseaseCiliaClinical DataComplementComplexCoughingCoupledDefense MechanismsDevelopmentDiseaseDissectionEnzymesEpithelial CellsFrequenciesFunctional disorderFundingGeneticGoalsHomeostasisHost Defense MechanismHumanHuman bodyHypersensitivityImmunologyIn VitroInflammationInflammatoryInflammatory ResponseInterdisciplinary StudyInvestigationKnowledgeLeadLung InflammationMediator of activation proteinMedicalMedicineMethodsMucociliary ClearanceMucous MembraneMucous body substanceMusNasal EpitheliumNasal cavityNervous system structureNeurosecretory SystemsNoseNucleosidesNucleotidesOperative Surgical ProceduresOtolaryngologyOxygenPathogenesisPatientsPhysiologicalPhysiologyPrimary Ciliary DyskinesiasProcessPurinergic P1 ReceptorsRecoveryRegulationResearchResolutionRespiratory FailureRoleScanningSignal PathwaySinusSneezingSpeedStructure of mucous membrane of noseTestingTherapeuticUnited StatesWorkadenosine deaminaseairway epitheliumairway surface liquidbasechronic rhinosinusitiseffective therapyimprovedin vivonew therapeutic targetnovel therapeuticspathogenpre-clinicalprogramsreceptorshear stresstheoriestherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chronic rhinosinusitis (CRS) is a very common upper airway disease affecting more than 31 million Americans. Current therapeutic strategies for CRS include both medical and surgical treatments; one major goal of these treatments is to improve the nasal mucociliary clearance (MCC) function in CRS patients, as this may reverse the diseased sinonasal mucosa to achieve physiological recovery. Adenosine is a ubiquitous nucleoside normally present in the airway lumen and interstitium. Previous in vitro studies have shown that adenosine is the major regulator for nasal airway surface liquid homeostasis. It can also increase cilia beating frequency of cultured human nasal epithelium. In our preliminary in vivo studies, a potent effect of adenosine, but not ATP, to accelerate nasal MCC was also observed. These findings indicate that adenosine and its receptors may be of great therapeutic value for CRS by speeding up nasal MCC. In addition to regulating MCC, adenosine has also been shown to elicit both anti- and pro-inflammatory effects. Although previous studies in the lower airways have revealed that adenosine enhances inflammation, our preliminary studies have shown that adenosine is not pro-inflammatory in the nose and sinuses. Based on all of these findings, we hypothesize that adenosine is the key factor to enhance the nasal MCC in vivo (Aim 1) and its anti-inflammatory actions will attenuate the development of CRS (Aim 2). The effect of adenosine on nasal MCC will be tested in vivo at both healthy and inflamed nose and sinuses. The underlying mechanisms will be determined at both in vivo and in vitro levels. The role of adenosine and adenosine receptors in CRS development, progression, and resolution will also be examined. We believe that the completion of this translational project will lead to a novel therapeutic strategy for CRS. It will also be of great significance to enhancing our knowledge of adenosine airway biology and re-evaluating the unified airway theory.
PUBLIC HEALTH RELEVANCE: Chronic rhinosinusitis (CRS) is a very common inflammatory disease in the nose and sinuses. Currently, both medical and surgical therapies are used for CRS patients; however, many patients still present with persistent inflammation even after aggressive treatment. In the proposed studies, we will examine the role of adenosine, a common mediator in human body, and its receptors, in CRS development, and explore the therapeutic value of targeting adenosine receptors for the treatment of CRS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations
-
批准号:10733754
-
项目类别:
-
资助金额:$62.22万
-
财政年份:2023
-
负责人:Xiaoyang Hua
-
依托单位:
海外基金